Group Effect in Full Replicate Design [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2018-09-12 15:31 (1109 d 14:33 ago) – Posting: # 19278
Views: 5,324

Hi GM,

» » For the ABE part (if swR <0.294) like the FDA’s Model II:
  • fixed:
    » » Group, Sequence, Treatment, Period (nested within Group), Group-by-Sequence Interaction
    » »
  • random:
    » » Subject (nested within Group × Sequence)

»
» But as per Progesterone Guidance, Treatment as random term in Average BE.

No way.

» Please see model SAS code from guidance.
»
» MODEL LAUCT = SEQ PER TRT/ DDFM=SATTERTH;
» RANDOM TRT/TYPE=FA0(2) SUB=SUBJ G;

Please make yourself familiar with the syntax of SAS’ PROC MIXED. Terms in the MODEL argument are fixed.

» As per your version, Subject (nested within Group × Sequence) is the random term.
»
» Now am Confused:ponder:,Which is the correct one?

Mine. For the exact setup ask a qualified SAS-coder.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,699 posts in 4,537 threads, 1,542 registered users;
online 7 (0 registered, 7 guests [including 6 identified bots]).
Forum time: Sunday 06:04 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5